Merck KGaA’s rare-tumor program notched another FDA win as Pimjetmi received approval for tenosynovial giant cell tumor. The company framed the approval as a continuation of its strategy to build a focused portfolio in rare cancers it can pair with targeted biology and clinical development assets licensed through prior deals. The approval also reinforces Merck KGaA’s broader push to expand beyond mainstream oncology indications, where smaller patient populations can still deliver commercially and clinically meaningful outcomes when the mechanism and endpoint selection are aligned. For investors and partners, the milestone signals ongoing regulatory progress for the Germany-based company’s rare-disease and oncology adjacency pipeline.